AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25249305 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 25249305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 36
Study 25249305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22456026 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐OCT guidance
Number of subjects: 70
Study 22456026 — intervention group
Group type: COMPARATOR
Intervention: IVUS guidance
Number of subjects: 70
Study 20883925 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 2645
Study 18571082 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-injection ring system
Number of subjects: 96
Study 18571082 — intervention group
Group type: COMPARATOR
Intervention: No data-injection system
Number of subjects: 96
Study 16025732 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hypnotic procedure using the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A)
Number of subjects: 0
Study 16025732 — intervention group
Group type: COMPARATOR
Intervention: Indirect hypnotic procedure using the Alman‐Wexler Indirect Hypnotic Susceptibility Scale (AWIHSS)
Number of subjects: 0
Study 12064813 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg/day
Number of subjects: 79
Study 12064813 — intervention group
Group type: COMPARATOR
Intervention: Rufloxacin 400 mg/week
Number of subjects: 79
Study 10495686 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol administration at an initial dose of 25 mg/day (12.5 mg for class III-IV patients), increased to a maximum of 200 mg/day
Number of subjects: 3991
Study 10495686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study 7588348 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl plus sclerotherapy with polidocanol
Number of subjects: 126
Study 7588348 — intervention group
Group type: COMPARATOR
Intervention: Conventional sclerotherapy with polidocanol alone
Number of subjects: 126
Study 1773685 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support system for insulin-dose adjustment
Number of subjects: 42
Study 1773685 — intervention group
Group type: COMPARATOR
Intervention: Recommendations from the education team (Control)
Number of subjects: 42
Study 7065660 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied mechlorethamine hydrochloride
Number of subjects: 42
Study 7065660 — intervention group
Group type: COMPARATOR
Intervention: Total-skin electron-beam irradiation
Number of subjects: 42
Study 30639231 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa seed oil (2.5 mL every 12 hours for 3 months)
Number of subjects: 120
Study 30639231 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa seed oil
Number of subjects: 120
Study 30639231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28688693 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Accelerated Radiotherapy (VART): 64.8Gy/3.5 weeks
Number of subjects: 179
Study 28688693 — intervention group
Group type: COMPARATOR
Intervention: Conventional CRT: 70Gy/7 weeks + 3 cycles carboplatin-5FU
Number of subjects: 179
Study 28688693 — intervention group
Group type: COMPARATOR
Intervention: Moderately accelerated CRT: 70Gy/6 weeks + 2 cycles carboplatin-5FU
Number of subjects: 179
Study 28688693 — intervention group
Group type: COMPARATOR
Intervention: Strongly intensified CRT: 64Gy/5 weeks + cisplatin (days 2, 16, 30) and 5 FU (days 1-5, 29-33) followed by 2 cycles adjuvant cisplatin-5FU
Number of subjects: 179
Study 25855918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of arginine (5.7 g per day)
Number of subjects: 84
Study 25855918 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose of arginine (12.3 g per day)
Number of subjects: 84
Study 25855918 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of arginine (18.9 g per day)
Number of subjects: 84
Study 24622416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG over four days
Number of subjects: 58
Study 24622416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24622416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG
Number of subjects: 58
Study 21878823 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training program for 6 weeks, 3 days per week
Number of subjects: 30
Study 21878823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 18661120 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC advised insulin infusion
Number of subjects: 34
Study 18661120 — intervention group
Group type: COMPARATOR
Intervention: Standard care insulin algorithms
Number of subjects: 34
Study 18661120 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC advised glucose measurement interval
Number of subjects: 34
Study 17980184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 215
Study 17980184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 15202162 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (single oral dose)
Number of subjects: 33
Study 15202162 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (2 intravenous doses of 0.15 mg/kg followed by 1 oral dose)
Number of subjects: 33
Study 11911549 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (higher dosages)
Number of subjects: 82
Study 11911549 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and carbidopa (lower dosages)
Number of subjects: 82
Study 11911549 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 82
Study 9832658 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate tissue adhesive
Number of subjects: 136
Study 9832658 — intervention group
Group type: COMPARATOR
Intervention: Monofilament sutures
Number of subjects: 136
Study 7522132 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 25
Study 7522132 — intervention group
Group type: COMPARATOR
Intervention: Cocaine infusion
Number of subjects: 25
Study 7522132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine users (baseline)
Number of subjects: 25
Study 7522132 — intervention group
Group type: COMPARATOR
Intervention: Nonusers (baseline)
Number of subjects: 25
Study 2563317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.15 mg.kg‐1
Number of subjects: 98
Study 2563317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.15 mg.kg‐1
Number of subjects: 98
Study 2563317 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 98
Study 4802598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated employees in factories
Number of subjects: 51219
Study 4802598 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated telecommunications units
Number of subjects: 51219
Study 4802598 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls in telecommunications units
Number of subjects: 51219
Study 31604416 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice-based preventive health checks
Number of subjects: 364
Study 31604416 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smoking
Number of subjects: 364
Study 31604416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk alcohol consumption
Number of subjects: 364
Study 31604416 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 364
Study 31604416 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor lung function
Number of subjects: 364
Study 27749739 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg/d)
Number of subjects: 1616
Study 27749739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1616
Study 25919636 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 139
Study 25919636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 23514773 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 2341
Study 23514773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2341
Study 21771304 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Electric Asymmetric Treatment (REAC) using Neuro Psycho Physical Optimization (NPPO) for 4 weeks
Number of subjects: 888
Study 21771304 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 888
Study 19467365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel 0.025% for 3 days
Number of subjects: 0
Study 19467365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel 0.05% for 2 or 3 days
Number of subjects: 0
Study 19467365 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel for 3 days
Number of subjects: 0
Study 16323095 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg daily for 7-14 days)
Number of subjects: 394
Study 16323095 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (500 mg daily for 7-14 days)
Number of subjects: 394
Study 14982609 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 73
Study 14982609 — intervention group
Group type: COMPARATOR
Intervention: Breath Awareness
Number of subjects: 73
Study 11467760 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 20
Study 11467760 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 20
Study 10190078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive course of high fractional X‐ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5‐fluorouracil (5‐FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g.
Number of subjects: 48
Study 10190078 — intervention group
Group type: COMPARATOR
Intervention: Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention, with repeated courses (100 mg/per course) 6 months after surgical operation.
Number of subjects: 48
Study 8068375 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of questionnaires to non-respondents
Number of subjects: 1732
Study 8068375 — intervention group
Group type: COMPARATOR
Intervention: Postal survey
Number of subjects: 1732
Study 8068375 — intervention group
Group type: COMPARATOR
Intervention: Telephone approach
Number of subjects: 1732
Study 8068375 — intervention group
Group type: COMPARATOR
Intervention: Postal non-respondents
Number of subjects: 1732
Study 3395733 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory therapy
Number of subjects: 40
Study 3395733 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptive therapy
Number of subjects: 40
Study 3395733 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 30509427 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic technique
Number of subjects: 75
Study 30509427 — intervention group
Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 75
Study 28532387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab added to chemotherapy
Number of subjects: 1574
Study 28532387 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalized regression models using adaptive lasso
Number of subjects: 1574
Study 28532387 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cross-validation
Number of subjects: 1574
Study 28532387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model with 4 clinical covariates, 98 biomarkers, and 24 biomarker-by-treatment interactions
Number of subjects: 1574
Study 26380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangyabao serial drugs combined with Western medicine (WM)
Number of subjects: 199
Study 26380442 — intervention group
Group type: COMPARATOR
Intervention: Simulative agents of Jiangyabao serial drugs combined with Western medicine (WM)
Number of subjects: 199
Study 26380442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hypotensive treatment program with Nifedipine Sustained Release Tablet and Hydrochlorothiazide
Number of subjects: 199
Study 24432069 — intervention group
Group type: EXPERIMENTAL
Intervention: Swim cast
Number of subjects: 68
Study 24432069 — intervention group
Group type: COMPARATOR
Intervention: Traditional cast
Number of subjects: 68
Study 20333384 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-Irinotecan (HA 1,000 mg/m(2) and irinotecan at 350 mg/m(2))
Number of subjects: 76
Study 20333384 — intervention group
Group type: COMPARATOR
Intervention: irinotecan (350 mg/m(2))
Number of subjects: 76
Study 20333384 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-Irinotecan
Number of subjects: 76
Study 20333384 — intervention group
Group type: COMPARATOR
Intervention: irinotecan
Number of subjects: 76
Study 19060449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (PM)
Number of subjects: 19
Study 19060449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16927582 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram adherence intervention with trained care managers
Number of subjects: 228
Study 12508081 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) and hydrocortisone supplementation (6 micro g.kg(‐1).d(‐1) of T3 with 1 mg.kg(‐1).d(‐1) of hydrocortisone)
Number of subjects: 253
Study 12508081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 253
Study 12508081 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and hydrocortisone supplementation
Number of subjects: 253
Study 10335931 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg p.o. twice a day
Number of subjects: 173
Study 10335931 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g i.v. as a single daily dose
Number of subjects: 173
Study 8915757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rIL-2 immunotherapy (daily administration)
Number of subjects: 8
Study 8915757 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic rIL-2 infusion following intrathecal treatment
Number of subjects: 8
Study 8915757 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical condition post-treatment
Number of subjects: 8
Study 8915757 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal rIL-2 treatment side effects
Number of subjects: 8
Study 12284145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemeprost 1 mg pessaries
Number of subjects: 1030
Study 12284145 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 10 mg pessaries
Number of subjects: 1030
Study 387070 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) administered as a single 10 ml intravenous infusion during surgery.
Number of subjects: 50
Study 387070 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as a single 10 ml intravenous infusion during surgery.
Number of subjects: 50
Study 31147187 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 90
Study 31147187 — intervention group
Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 90
Study 28864487 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 69
Study 28864487 — intervention group
Group type: COMPARATOR
Intervention: Pap screening (HCP-administered)
Number of subjects: 69
Study 26291445 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 0
Study 26291445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24122077 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy measurements using Datex-Ohmeda-M-EntropyTM module
Number of subjects: 27
Study 24122077 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard sedation regimen (propofol and fentanyl)
Number of subjects: 27
Study 22522428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (9-month after school program)
Number of subjects: 0
Study 22522428 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 19398687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 800
Study 17199579 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol ointment
Number of subjects: 5
Study 17199579 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 5
Study 17199579 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 5
Study 15750763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 2702
Study 15750763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702
Study 11939866 — intervention group
Group type: EXPERIMENTAL
Intervention: H perforatum (St John's wort)
Number of subjects: 340
Study 11939866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 340
Study 11939866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 9790546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy plus placebo
Number of subjects: 739
Study 9790546 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy plus flutamide
Number of subjects: 739
Study 7896149 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day for 3 days
Number of subjects: 32
Study 7896149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 32
Study 2896826 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin
Number of subjects: 3801
Study 2896826 — intervention group
Group type: EXPERIMENTAL
Intervention: LPF-toxoid vaccine
Number of subjects: 3801
Study 2896826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaccine solvent)
Number of subjects: 3801
Study 31937513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) 50-200 mg/day
Number of subjects: 1957
Study 31937513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1957
Study 31937513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV)
Number of subjects: 1957
Study 29623812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle Mimicking Prosthetic Foot 4.0
Number of subjects: 18
Study 29623812 — intervention group
Group type: COMPARATOR
Intervention: Current prosthesis
Number of subjects: 18
Study 28835228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 International Units cholecalciferol monthly)
Number of subjects: 0
Study 28835228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (arachidis oleum raffinatum)
Number of subjects: 0
Study 28835228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 0
Study 28835228 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma subtype, site, and stage
Number of subjects: 0
Study 25462419 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily HF-rTMS (10 Hz) over the left dorsolateral prefrontal cortex for 2 weeks (60,000 pulses)
Number of subjects: 27
Study 23619819 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg meloxicam tablet
Number of subjects: 24
Study 23619819 — intervention group
Group type: COMPARATOR
Intervention: 15 mg meloxicam suspension
Number of subjects: 24
Study 21073813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercept oral specimen collection device
Number of subjects: 21
Study 21073813 — intervention group
Group type: COMPARATOR
Intervention: Statsure Saliva Sampler
Number of subjects: 21
Study 21073813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 21
Study 18985552 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes incorporating an unstable sole (Masai Barefoot Technology), worn for a minimum of two hours per day for eight weeks.
Number of subjects: 10
Study 18985552 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes incorporating an unstable sole (Masai Barefoot Technology)
Number of subjects: 10
Study 20103575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation and early rehabilitation (28 patients)
Number of subjects: 60
Study 20103575 — intervention group
Group type: COMPARATOR
Intervention: Standard care (32 patients)
Number of subjects: 60
Study 16275368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (100/50 microg)
Number of subjects: 26
Study 16275368 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone (100 microg)
Number of subjects: 26
Study 11459288 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted erythrocyte suspensions (LD-SAGM)
Number of subjects: 279
Study 11459288 — intervention group
Group type: COMPARATOR
Intervention: Non-leukocyte-depleted erythrocyte suspensions (SAGM)
Number of subjects: 279
Study 11459288 — intervention group
Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 279
Study 9587122 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate carcinoma tissue
Number of subjects: 26
Study 9587122 — intervention group
Group type: COMPARATOR
Intervention: Benign hyperplasia tissue
Number of subjects: 26
Study 7870725 — intervention group
Group type: EXPERIMENTAL
Intervention: Local applications of rifampicin and dimexide solutions
Number of subjects: 287
Study 7870725 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccine
Number of subjects: 287
Study 3163523 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% xylitol
Number of subjects: 11
Study 3163523 — intervention group
Group type: COMPARATOR
Intervention: 2.5% sucrose
Number of subjects: 11
Study 3163523 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 11
Study 31618132 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast radiotherapy (RT) after breast-conserving surgery (BCS)
Number of subjects: 748
Study 31618132 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (RT) after breast-conserving surgery (BCS)
Number of subjects: 748
Study 29848993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (SB) loading regimen (up to 100 mg∙kg‐1 for 10 days)
Number of subjects: 58